Literature DB >> 3622306

Influence of cyclandelate on in vitro red blood cell deformability.

D W Hall, W E van den Hoven.   

Abstract

Using filtration and viscosity techniques, cyclandelate, some of its metabolites and flunarizine were evaluated to determine their ability to maintain human red blood cell (RBC) deformability. In filtration studies, RBC suspensions were metabolically depleted, which decreased the capacity of the cells to pass through narrow filter pores. In viscosity measurements performed with whole blood, metabolic depletion resulted in an increase of blood viscosity values. The results of these experiments appeared to indicate that cyclandelate, cyclandelate alcohol and flunarizine were approximately equipotent in maintaining RBC filtration and blood viscosity values. Cyclandelate acid appeared to be less active in both studies. By measuring the adenosine triphosphate content of red blood cells it has been shown that this activity is not due to an action on red blood cell energy metabolism. Finally, experiments conducted with the calcium chelator EGTA showed that the activity of cyclandelate was reduced in the absence of Ca++ ions. The results strengthen the hypothesis that cyclandelate maintains red cell deformability by inhibiting calcium entry through the red cell membrane.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622306     DOI: 10.2165/00003495-198700332-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  16 in total

1.  Red cell deformability: physiological, clinical and pharmacological aspects.

Authors:  G A Marcel
Journal:  J Med       Date:  1979

2.  A simple method for measuring erythrocyte deformability.

Authors:  H L Reid; A J Barnes; P J Lock; J A Dormandy; T L Dormandy
Journal:  J Clin Pathol       Date:  1976-09       Impact factor: 3.411

3.  Effect of flunarizine on the human red cell shape changes and calcium deposition induced by A 23187.

Authors:  F De Clerck; M Beerens; F Thoné; M Borgers
Journal:  Thromb Res       Date:  1981 Oct 1-15       Impact factor: 3.944

Review 4.  Red cell deformability.

Authors:  J A Dormandy
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

5.  Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.

Authors:  W E Van den Hoven; D W Hall; J W Burns
Journal:  Br J Clin Pract Suppl       Date:  1984

6.  Reduced erythrocyte deformability in diabetes.

Authors:  D E McMillan; N G Utterback; J La Puma
Journal:  Diabetes       Date:  1978-09       Impact factor: 9.461

7.  Impaired red cell deformability in peripheral vascular disease.

Authors:  H L Reid; J A Dormandy; A J Barnes; P J Lock; T L Dormandy
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

8.  Changes in red cell deformability and other haemorrheological variables after myocardial infarction.

Authors:  A J Dodds; M J Boyd; J Allen; E D Bennett; P T Flute; J A Dormandy
Journal:  Br Heart J       Date:  1980-11

Review 9.  Calcium ions, drug action and the red cell membrane.

Authors:  J S Wiley; K E McCulloch
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

10.  Heterogeneity of biochemical actions among vasodilators.

Authors:  F C Greenslade; C K Scott; K L Newquist; K M Krider; M Chasin
Journal:  J Pharm Sci       Date:  1982-01       Impact factor: 3.534

View more
  1 in total

1.  [Effects of cyclandelate on the CNS--a double-blind, placebo-controlled study of healthy subjects].

Authors:  W Dimpfel; P Netter; M Spüler; W Wedekind
Journal:  Klin Wochenschr       Date:  1991-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.